Federal award (PURCHASE ORDER, fiscal year 2021)
Recipient: CATALYST PHARMACEUTICALS, INC
Awarding agency: Department of Defense / Defense Threat Reduction Agency
Funding agency: Department of Defense / Defense Threat Reduction Agency
Period of performance: 2021-03-22 to 2022-03-01
Current total value of award: $86650
Description: RESEARCH AND DEVELOPMENT SERVICES TO CROSS-REFERENCE EXISTING REGULATORY COMMUNICATIONS AND SUBMISSIONS TO ALLOW A FACILE, EXPEDITED APPROVAL TO CONDUCT ADDITIONAL PRECLINICAL STUDIES.